Sugi Predict

Sugi Predict / Compounds / SCHEMBL24844

SCHEMBL24844

SCHEMBL24844

CON=C1CCc2cc(C=O)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.39
▸ MAPT P10636 5/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ NFKB1 P19838 2/20 0.39
▸ NFKB2 Q00653 2/20 0.39
▸ RELA Q04206 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HPGD P15428 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ ALDH1A3 P47895 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ AOX1 Q06278 1/20 0.36
▸ TRIM24 O15164 1/20 0.36
▸ ALDH5A1 P51649 1/20 0.36
▸ ABAT P80404 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ TRIM33 Q9UPN9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5106791 1.00 ALDH1A1 (0.39) ALDH1A1MAPTNPC1RAB9ANFKB1
SCHEMBL29854790 1.00 ALDH1A1 (0.39) ALDH1A1MAPTNPC1RAB9ANFKB1
SCHEMBL25790 0.82 HTT (0.40) ALDH1A1MAPTNPC1RAB9ANFKB1
SCHEMBL25791 0.82 HTT (0.40) ALDH1A1MAPTNPC1RAB9ANFKB1
SCHEMBL6659325 0.77 SRD5A1 (0.46) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL13606738 0.77 MAPT (0.47) ALDH1A1MAPTNPC1RAB9ANFKB1
SCHEMBL24842 0.76 MAPT (0.39) ALDH1A1MAPTNPC1RAB9ANFKB1
SCHEMBL29854633 0.76 SRD5A1 (0.42) ALDH1A1MAPTNPC1RAB9ANFKB1
SCHEMBL1855814 0.76 SRD5A1 (0.42) ALDH1A1MAPTNPC1RAB9ANFKB1
SCHEMBL1855812 0.76 SRD5A1 (0.42) ALDH1A1MAPTNPC1RAB9ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583856-B2 Inhibitors of protein kinase A BLUEPRINT MEDICINES CORPORATION (US) 2026-03-24 — — US disclosed
US-20240132490-A1 INHIBITORS OF PROTEIN KINASE A BLUEPRINT MEDICINES CORPORATION (US) 2024-04-25 — — US disclosed
WO-2022165402-A1 INHIBITORS OF PROTEIN KINASE A BLUEPRINT MEDICINES CORPORATION (US) 2022-08-04 — — WO disclosed
CN-103159735-B The imidazoles kinase inhibitor replaced TONGHUA JIDA PHARMACEUTICAL CO., LTD. (CN) 2015-12-09 — — CN disclosed
CN-103159736-B Substitutional pyrazol kinase inhibitor TONGHUA JIDA PHARMACEUTICAL CO LTD 2015-05-13 — — CN disclosed
CN-103159736-A Substitutional pyrazol kinase inhibitor TONGHUA SIHUAN PHARM CO LTD 2013-06-19 — — CN disclosed
CN-103159735-A Substitutional imidazole kinase inhibitor TONGHUA SIHUAN PHARM CO LTD 2013-06-19 — — CN disclosed
WO-2012026403-A1 CONDENSED RING COMPOUND 日本曹達株式会社 (JP) 2012-03-01 — — WO disclosed
US-7452906-B2 Pyridine derivatives as Raf kinase inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2008-11-18 — — US disclosed
US-20080108615-A1 Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors SMITHKLINE BEECHAM P.L.C 2008-05-08 — — US disclosed
EP-1423384-A1 PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2004-06-02 — — EP disclosed
EP-1397354-A1 IMIDAZOLE-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2004-03-17 — — EP disclosed
US-20040038964-A1 Imidazole derivatives as raf kinase inhibitors SMITHKLINE BEECHAM P.L.C. (GB) 2004-02-26 — — US disclosed
CN-1471523-A Imidazole derivatives as Raf kinase inhibitors ʷ 2004-01-28 — — CN disclosed
WO-2003086467-A1 CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR SMITHKLINE BEECHAM CORPORATION (US) 2003-10-23 — — WO disclosed
EP-1318992-A1 IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2003-06-18 — — EP disclosed
WO-2003022833-A1 PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2003-03-20 — — WO disclosed
WO-2003022840-A1 PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2003-03-20 — — WO disclosed
WO-2002094808-A1 IMIDAZOLE-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2002-11-28 — — WO disclosed
WO-2002024680-A1 IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583856-B2 Inhibitors of protein kinase A CSNK1A1, CSNK1A1L, CSNK1G1 ALDH1A1 2595/4885MAPT 4258/4885NPC1 944/4885
US-20240132490-A1 INHIBITORS OF PROTEIN KINASE A PRKCA, MAP3K6, MAP3K1 ALDH1A1 2528/4885MAPT 1253/4885NPC1 2657/4885
US-20040038964-A1 Imidazole derivatives as raf kinase inhibitors BRAF, RAF1, ARAF ALDH1A1 1835/4885MAPT 850/4885NPC1 1281/4885
US-20080108615-A1 Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors BRAF, RAF1, ARAF ALDH1A1 1372/4885MAPT 970/4885NPC1 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.